Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of pomalidomide in treating
patients with Waldenstrom macroglobulinemia that has returned after a period of improvement
(relapsed) or does not respond to treatment (refractory). Pomalidomide may stimulate the
immune system in different ways and stop cancer cells from growing.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Celgene Corporation National Cancer Institute (NCI)